Hosted on MSN10h
Nammi Therapeutics doses first subject in trial of QXL138AM for multiple myeloma
Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...
emjreviews.com17h
Study Finds Genetic Link to Multiple Myeloma Risk, Suggests Genetic Testing for High-Risk Patients
A new study finds that pathogenic germline variants (PGVs) in cancer predisposition genes like BRCA1 and BRCA2 increase the risk of multiple ...
Unveiling the secrets of aging: Scientists discover dual role of immunoglobulins
A team of scientists from the Chinese Academy of Sciences (CAS) and BGI Research has uncovered the intricate mechanisms by ...
The American Journal of Managed Care2d
Fexagratinib in MS Shows Promise for Human Use
The results from a new study of the multi-kinase inhibitor fexagratinib in mouse models are raising hopes that the therapy ...
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...
Medscape15d
Diagnostic Accuracy of Monoclonal Antibody Based Serum Immunoglobulin Free Light Chain Immunoassays in Myeloma Cast Nephropathy
Data were analysed using SPSS 17.0 for Windows. Spearman's correlation coefficient was used to assess the correlation of results between the two assays and Chi square test to assess the ...
Pharmaceutical Technology20d
J&J’s Darzalex combination gains expanded label for multiple myeloma in Europe
Credit: Michael Vi/Shutterstock The European label for Johnson and Johnson Innovation Medicine’s (J&J) Darzalex (daratumumab) has been expanded to include patients with newly diagnosed multiple ...